In other words, VPA and WT161 showed the same trend in regulating APP, BACE1, and PS-1 expression and the opposite trend in regulating ADAM10 expression, but both could reduce the concentration of soluble Aβ42 in AD cell models. This evidence concerns the gene PSEN1 and Alzheimer disease.